Syros Pharmaceuticals, Inc. - Common Stock (SYRS)

Competitors to Syros Pharmaceuticals, Inc. - Common Stock (SYRS)

Blueprint Medicines Corporation 

Blueprint Medicines focuses on targeted therapy for genomically defined cancers, which directly overlaps with some of Syros's development programs. Both companies are developing precision medicines, but Blueprint's advanced expertise in molecularly targeted drugs and its first-in-class treatments afford it a competitive advantage. Additionally, their robust clinical trial results often attract more investor interest and broader market presence compared to Syros.

Gilead Sciences, Inc. 

Gilead Sciences competes with Syros Pharmaceuticals primarily through its extensive portfolio of therapies for oncology and hematology. Gilead's experience in drug development and a strong pipeline of targeted therapies give it a competitive edge in bringing innovative treatments to market. Moreover, Gilead's established relationships with healthcare providers and payers may influence treatment choices in favor of their products, which allows them to capitalize on market share more effectively than Syros.

Iovance Biotherapeutics, Inc. 

Iovance is focused on cell therapy for cancer, developing tumor-infiltrating lymphocyte therapies that extend beyond the traditional pharmaceutical approaches Syros is pursuing. This fundamental differentiation in treatment modalities allows Iovance to carve out a niche in the immunotherapy landscape, which could pose a challenge for Syros's market positioning. Nevertheless, both companies share a commitment to advancing cancer treatment, making them indirect competitors with varying therapeutic paradigms.

Mirati Therapeutics, Inc.

Mirati Therapeutics specializes in genomically targeted therapies, particularly notable for their efforts in treating cancers driven by specific genetic mutations. While both Mirati and Syros operate in the oncology space, Mirati's established reputation and pipeline of promising therapies, including drug candidates that have reached advanced stages in trials, provide it with a significant advantage in both market perception and bargaining power in partnerships and collaborations.

Zymeworks Inc. 

Zymeworks is engaged in the development of biopharmaceuticals focusing on cancer and autoimmune disease, competing with Syros in the oncology market through its innovative drug platform. While Zymeworks offers a unique approach with its modular therapeutic platforms, Syros differentiates itself with its focus on gene control and precision therapies for specific cancer types. However, Zymeworks' more diversified pipeline may give it a relative advantage in attracting investment and partnerships compared to Syros.